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Abstract
Xanomeline is a unique agonist of muscarinic receptors that possesses functional selectivity at the M1 and M4 receptor
subtypes. It also exhibits wash-resistant binding to and activation of the receptor. In the present work we investigated the
consequences of this type of binding of xanomeline on the binding characteristics and function of the M1 muscarinic
receptor. Pretreatment of CHO cells that stably express the M1 receptor for 1 hr with increasing concentrations of
xanomeline followed by washing and waiting for an additional 23 hr in control culture media transformed xanomeline-
induced inhibition of [
3H]NMS binding from monophasic to biphasic. The high-affinity xanomeline binding site exhibited
three orders of magnitude higher affinity than in the case of xanomeline added directly to the binding assay medium
containing control cells. These effects were associated with a marked decrease in maximal radioligand binding and
attenuation of agonist-induced increase in PI hydrolysis and were qualitatively similar to those caused by continuous
incubation of cells with xanomeline for 24 hr. Attenuation of agonist-induced PI hydrolysis by persistently-bound
xanomeline developed with a time course that parallels the return of receptor activation by prebound xanomeline towards
basal levels. Additional data indicated that blockade of the receptor orthosteric site or the use of a non-functional receptor
mutant reversed the long-term effects of xanomeline, but not its persistent binding at an allosteric site. Furthermore, the
long-term effects of xanomeline on the receptor are mainly due to receptor down-regulation rather than internalization.
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Introduction
There are five subtypes of muscarinic acetylcholine receptors
that vary in their distribution and function. The M1 receptor
mediates its response to acetylcholine and pharmacological
agonists via coupling to the Gq/G11 class of heterotrimeric
guanine nucleotide-binding proteins (G proteins). The resultant
activation of phospholipase C leads to a subsequent increase in
phosphoinositide hydrolysis, which plays a role in cell growth,
survival, and differentiation [1,2]. Of the five cloned subtypes of
the muscarinic receptor, the M1 subtype is vital for processes
involved in learning and memory. Memory deficits such as those
seen in Alzheimer’s disease are currently treated with acetylcho-
linesterase inhibitors. However, this pharmacological approach is
endowed with serious untoward effects due to activation of all
subtypes of muscarinic receptors by the elevated levels of
acetylcholine. A proposed alternative is to administer M1-selective
muscarinic receptor agonists. Development of such agonists,
however, has been hampered by the highly conserved nature of
the orthosteric binding domain among the five receptor subtypes
[1,3,4].
Xanomeline (3-[3-hexyloxy-1,2,5-thiadiazo-4-yl]-1,2,5,6-tetra-
hydro-1-methylpyridine) is a novel agonist that has been studied
extensively due to its high potency and functional selectivity at M1
and M4 receptors [5–7] and its potential in the treatment of
cognitive deficits in schizophrenia [8]. In 1997, our laboratory
discovered that xanomeline activates the M1 muscarinic acetyl-
choline receptor in a unique wash-resistant manner, unlike other
classical muscarinic agonists such as carbachol [9]. Since then, it
has been shown that this type of activation is associated with wash-
resistant binding [10,11] and allosteric modulation [12] of the M1
receptor. There is evidence that xanomeline interacts reversibly
with the orthosteric site, while it binds persistently to the receptor
at a different secondary binding domain [10–12].
While the unique short-term effects of xanomeline have been
studied extensively, the long-term consequences of its persistent
binding remain relatively unknown. There is preliminary evidence
that although xanomeline wash-resistant receptor activation is
reversed over time, its effects in inhibiting binding of radioligands
to the orthosteric domain on the receptor were actually potentiated
[12,13]. However, the mechanisms underlying these changes have
yet to be explored. It is known that prolonged activation of G
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lead to modulation of receptor expression and response to agonists
[14,15]. The unique ability of xanomeline to persistently bind to
and activate the M1 receptor may similarly result in down-
regulation/desensitization of the receptor. Alternatively, persis-
tently-bound xanomeline may induce modification of the receptor
conformation over time. We undertook the current study to
further evaluate the possible mechanisms involved in the long-term
changes observed in receptor binding and function by the wash-
resistant component of xanomeline binding to the M1 receptor.
Results
Concentration-dependent changes in [
3H]NMS binding
to the M1 muscarinic receptor by xanomeline
pretreatment
The specific binding of 0.2 nM [
3H]NMS to the hM1
muscarinic receptor expressed in intact CHO cells was measured
in the continuous presence of xanomeline in naı ¨ve cells, or
following various xanomeline pretreatment and washing condi-
tions. As indicated in Fig. 1A, xanomeline is a potent inhibitor of
[
3H]NMS binding. In accordance with previous reports [12,17],
preincubation of cells with increasing concentrations of xanome-
line for 1 h followed by washing away free drug resulted in residual
concentration-dependent inhibition of [
3H]NMS binding, albeit
with a lower potency as compared to that observed in naı ¨ve cells
with xanomeline present in the binding assay mixture. In both
cases, the data were best described by a one-site binding model
(Table 1).
In order to assess the long-term effects of residual xanomeline
binding, xanomeline-treated and washed cells were incubated for
an additional 23 h in control culture medium. Visually apparent
changes in cell density were observed following this pretreatment
protocol with xanomeline. In order to account for these variances,
the method of Bradford [18] was used to quantify changes in
protein content in CHO hM1 cells. No changes were evident
following short-term exposure to xanomeline. However, concen-
tration-dependent decreases in protein content were observed
following 24-h pretreatment with concentrations of xanomeline
higher than 100 nM (6567% maximal decrease at 10 mM
xanomeline), or 1-h pretreatment followed by washing and
prolonged waiting (3262% maximal decrease at 10 mM xanome-
line). Therefore, the binding data for these experimental groups
were adjusted to account for the contribution of cell protein
reduction to the observed decrease in [
3H]NMS binding and are
presented in Fig. 1A. Further control experiments were designed
to determine if the changes in protein content following long-term
xanomeline pretreatments were due to exposure to the xanomeline
solvent, dimethylsulfoxide. CHO hM1 cells exposed to dimethyl-
sulfoxide in a manner similar to that employed for the various
xanomeline treatment protocols did not exhibit significant changes
in either protein content or [
3H]NMS binding (data not shown).
Preincubation of cells with increasing concentrations of xanome-
line for 1 h followed by washing and waiting for 23 h resulted in
the detection of two distinct binding states as determined by
nonlinear regression analysis (Fig. 1A and Table 1). Xanomeline
IC50 at the high-potency binding site that represented approxi-
mately half of the total receptor population was three orders of
magnitude lower than that observed prior to prolonged waiting. In
contrast, the IC50 of the lower-potency binding component of
xanomeline was comparable to, albeit significantly lower (p,0.05)
than that at the single site detected without waiting (Table 1). It is
also worth noting that maximal inhibition of [
3H]NMS binding
was incomplete at 8463%. This is in contrast to the complete
inhibition of binding observed prior to prolonged waiting. A
similar two-site binding profile was evident when cells were
preincubated with xanomeline for 24 h followed by washing away
free drug, with slightly higher potencies at both sites as compared
to 1-h pretreatment followed by washing and waiting 23 h (Fig. 1A
and Table 1).
Comparison of the effects of treatment with carbachol or
xanomeline on [
3H]NMS binding to the M1 muscarinic
receptor
To test the uniqueness of the observed long-term effects of
xanomeline on [
3H]NMS binding, we repeated the above
experiments in CHO hM1 cells utilizing the classical reversible
Figure 1. Inhibition of [
3H]NMS binding by (A) xanomeline or
(B) carbachol in CHO cells stably expressing human M1
muscarinic acetylcholine receptors. The specific binding of
0.2 nM [
3H]NMS was measured in the presence of increasing
concentrations of agonist in naı ¨ve cells (closed squares), or after
pretreating with increasing concentrations of agonist for 1 h (open
circles) or 24 h (open diamonds) followed by washing and immediate
use in the binding assay, or after pretreating with increasing
concentrations of agonist for 1 h followed by washing and incubation
in agonist-free media for an additional 23 h before use in the binding
assay (closed circles). Nonspecific binding was defined by 10 mM
atropine. Values represent the means 6 standard error of four to six
experiments conducted in triplicate.
doi:10.1371/journal.pone.0015722.g001
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in protein content were only observed following 24-h pretreatment
with concentrations of carbachol higher than 0.1 mM (2666.6%
maximal decrease at 10 mM carbachol). Therefore, raw data were
normalized for protein content. As shown in Fig. 1B, concomitant
presence of carbachol and [
3H]NMS in the binding assay resulted
in concentration-dependent and complete inhibition of radioli-
gand binding. Nonlinear regression analysis revealed that the data
were best described by a one-site binding model, with a calculated
carbachol IC50 of ,500 mM (Table 1). Unlike xanomeline,
carbachol pretreatment for 1 h followed by washing away free
drug did not result in a significant reduction in [
3H]NMS binding.
Similarly, 1-h preincubation with carbachol followed by washing
and 23-h wait caused only a slight decrease in [
3H]NMS binding
at the highest concentration (10 mM) (Fig. 1B). However, 24-h
carbachol pretreatment followed by washing away free drug
resulted in a concentration-dependent decrease in radioligand
binding with a potency three orders of magnitude higher than that
observed by exposure of naı ¨ve cells to carbachol only during the
binding assay (Fig. 1B, Table 1). Nonlinear regression analysis of
the data yielded a one-site binding model. This is in sharp contrast
to the distinct two binding sites observed following similar
pretreatment with xanomeline (Fig. 1A).
Effects of xanomeline pretreatment on saturation
binding of [
3H]NMS
Saturation binding experiments were designed to test whether
the long-term effects of xanomeline treatments on radioligand
binding are the result of reduction in radioligand affinity, maximal
binding, or both. The ability of increasing concentrations of
[
3H]NMS to bind to the hM1 receptor in untreated CHO hM1
cells was compared with that in cells subjected to the various
xanomeline pretreatment conditions used in the experiments
described above. Pretreatment with 300 nM xanomeline for 1 h
followed by washing away free drug did not result in changes in
radioligand affinity or maximal cell-surface receptor density
(Fig. 2A, Table 2). However, a profound decrease in the maximal
binding of [
3H]NMS was observed 23 h after washing away free
drug. The magnitude of this decrease was similar to that detected
in cells incubated with the same concentration of xanomeline for
24 h before washing away free drug. Interestingly, a concomitant
marked increase in [
3H]NMS affinity was observed in the latter
two groups. Results are summarized in Table 2.
A similar pattern of changes in maximal binding was observed
when the concentration of xanomeline used for pretreatments was
increased to 3 mM (Fig. 2B). However, decreases in [
3H]NMS
affinity were observed following 1-h and 24-h pretreatment
Table 1. Effects of xanomeline or carbachol pretreatments on 0.2 nM [
3H]NMS binding in CHO hM1,r M 1, or mutant
123 cells.
Xanomeline Carbachol
pIC50
a pIC50 high
b pIC50 low
c Imax
d pIC50 Imax
CHO hM1
Control
e,f 6.260.07 100 3.360.01 9960.3
1 h washout 5.760.05* 9760.8
1 h washout/23 h wait 8.660.21
{
(4362.4%)
5.060.06
{ 8462.8
{
24 h washout 9.560.13
{
(4365.6%)
5.760.06 9660.8 6.360.08 8561.6
{
CHO rM1 n.m.
g
Control 7.360.14 9960.6
1 h washout 6.060.06* 9560.5
1 h washout/23 h wait 7.160.16
{
(7461.1%)
4.660.23
{ 9962.3
24 h washout 9.460.20
{
(4767.7%)
6.660.12 9760.5
CHO rM1 mutant
123 n.m.
g
Control 7.660.14 9960.5
1 h washout 6.060.02* 9660.7
1 h washout/23 h wait 4.960.23
{ 6067.4
{
24 h washout 5.860.08 9062.9
Cells were pretreated with increasing concentrations of xanomeline or carbachol for 1 h or 24 h at 37uC followed by washing and immediate use in the binding assay or
further incubation in the absence of free xanomeline for 23 h. Cells were then incubated with 0.2 nM [
3H]NMS at 37uC for 1 h. Data were corrected for protein as
indicated in results. Parameters derived from nonlinear regression analysis are shown as mean 6 S.E.M. of four to six experiments conducted in triplicate.
aNegative logarithm of the IC50 for binding to a single affinity site.
bNegative logarithm of the IC50 for the high-affinity agonist binding site; percentage of binding sites shown in parentheses.
cNegative logarithm of the IC50 for the low-affinity agonist binding site.
dMaximal percentage inhibition of [
3H]NMS binding.
eControl, naı ¨ve cells were incubated simultaneously with agonist and radioligand.
fResults shown for xanomeline in control CHO hM1 cells are from nonlinear regression analysis with the bottom constrained to be greater than 0.
gNot measured.
*Significant difference (p,0.05) in pIC50 between control and 1 h washout as determined by students unpaired t-test.
{Significant difference (p,0.05) in pIC50 between the indicated groups and 1 h washout as determined by one-way ANOVA with Dunnett’s post-test.
{Significant difference (p,0.05) of Imax from 100 percent.
doi:10.1371/journal.pone.0015722.t001
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h pretreatment with xanomeline on radioligand affinity were
reduced when washed cells were incubated for 23 h in the absence
of free xanomeline (Table 2).
Effects of xanomeline pretreatment on agonist-
stimulated production of inositol phosphates
Assays of muscarinic acetylcholine receptor-mediated PI
hydrolysis were undertaken to ascertain the functional conse-
quences of wash-resistant xanomeline binding at the hM1
muscarinic receptor. Initial experiments were performed to
establish concentration-response characteristics of xanomeline in
comparison to those of the classical agonists carbachol and
oxotremorine in CHO hM1 cells (Fig. 3). The maximal
accumulation of inositol phosphates induced by xanomeline,
carbachol and oxotremorine was similar in magnitude (Emax values
of 1100061100; 110006800; 100006800 dpm, respectively).
However, xanomeline was more potent than carbachol or
oxotremorine (pEC50 of 7.660.09; 5.760.11; 6.760.04, respec-
tively). Pretreatment with 300 nM xanomeline for 1 h followed by
washing away free drug resulted in a marked increase in basal
receptor activity (that corresponded to more than 60% of maximal
stimulation by carbachol). Subsequent stimulation of xanomeline-
pretreated cells with increasing concentrations of oxotremorine or
xanomeline (Figs. 4B and 4C, open circles), but not carbachol
(Fig. 4A, open circles) generated further slight increase in PI
hydrolysis (in individual experiments). Of particular interest, the
effects of xanomeline pretreatment on basal levels were reversed
when xanomeline-pretreated cells were incubated in the absence
of free xanomeline for 23 h (Fig. 4, closed circles). This reversal was
accompanied by a decrease in the maximal responses to carbachol,
oxotremorineandxanomelineby20,70and40%,respectively.The
potency of studied agonists to stimulate PI hydrolysis was also
reduced as evidenced by 10-, 32- and 11-fold increases in the EC50
for carbachol, oxotremorine and xanomeline, respectively. Similar
results were obtained when cells were continuously pretreated with
xanomeline for 24 h followed by washing away free drug, although
reductions of the maximal responses elicited by xanomeline and
Figure 2. Effects of xanomeline pretreatment, followed by
washout, on [
3H]NMS saturation binding in CHO cells stably
expressing human M1 muscarinic acetylcholine receptors. Cells
were pretreated with (A) 300 nM or (B)3mM xanomeline for 1 h (open
circles) or 24 h (open diamonds) followed by washing and immediate
use in the binding assay, or after pretreating with xanomeline for 1 h
followed by washing and incubation in agonist-free media for an
additional 23 h before use in the binding assay (closed circles).
Untreated (closed squares) and pretreated cells were subsequently
incubated for 1 hour at 37uC with increasing concentrations of
[
3H]NMS. Nonspecific binding was defined by 10 mM atropine. Values
represent the means 6 standard error of three to ten experiments
conducted in triplicate.
doi:10.1371/journal.pone.0015722.g002
Table 2. Effects of xanomeline pretreatment on [
3H]NMS
saturation binding parameters in CHO hM1,r M 1, and
mutant
123 cells.
300 nM xanomeline 3 mM xanomeline
KD
a (nM) Bmax
b KD (nM) Bmax
CHO hM1
Control
c 0.3560.02 910061600 0.2560.03 850061000
1 h washout 0.3860.04 890061400 0.5960.12* 850061100
1 h washout/23 h
wait
0.2160.04* 24006170* 0.3860.09 18006150*
24 h washout 0.2160.04* 21006250* 0.6360.17* 21006380*
CHO rM1 n.m.
d
Control 0.2760.08 2200690
1 h washout 0.4060.04 26006430
1 h washout/23 h
wait
0.3060.04 11006150*
24 h washout 0.6060.12* 13006150
CHO mutant
123 n.m.
d
Control 0.1960.02 27006300
1 h washout 0.4260.10 30006380
1 h washout/23 h
wait
0.2660.07 34006610
24 h washout 0.4960.11 36006320
Cells were pretreated with 300 nM or 3 mM xanomeline for 1 h or 24 h at 37uC
followed by washing and immediate use in the binding assay or for 1 h
followed by washing and further incubation in the absence of free xanomeline
for 23 h. Cells were then incubated with increasing concentrations of [
3H]NMS
at 37uC for 1 h. Parameters derived from computer-assisted non-linear
regression analysis as described in Methods are presented as mean 6 S.E.M. of
three to ten experiments conducted in triplicate.
aEquilibrium dissociation constant for [
3H]NMS binding.
bMaximal cell-surface receptor density (dpm/100,000 cells).
cControl, naı ¨ve cells were incubated with radioligand.
dNot measured.
*ANOVA followed by Dunnett’s post-test detected a significant difference
(p,0.05) in KD or Bmax between the pretreated groups compared with vehicle
control.
doi:10.1371/journal.pone.0015722.t002
Long-Term Effects of Xanomeline on M1 Receptors
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15722oxotremorine were more evident (Fig. 4, open diamonds). Results
are summarized in Table 3.
Concentration dependence of xanomeline-induced long-
term changes in receptor sensitivity
Additional functional experiments were undertaken to deter-
mine the potency of xanomeline in producing its long-term
functional effects. CHO hM1 cells were subjected to pretreatment
with increasing concentrations of xanomeline (1 fM-10 mM) for
1 h followed by washing and waiting for 23 h or pretreatment
continuously for 24 h as previously described. Subsequently, cells
were stimulated with carbachol, oxotremorine or xanomeline at
either EC50 (1 mM, 0.1 mM, or 0.03 mM, respectively) or maximal
(10 mM, 1 mM, or 0.1 mM, respectively) concentrations. As
shown in Fig. 5A (open symbols), pretreatment with xanomeline
for 1 h followed by washing and waiting for 23 h resulted in
comparable concentration-dependent decreases in PI hydrolysis
elicited by EC50 concentrations of all three agonists used.
However, a more potent concentration-dependent decrease was
observed following prolonged continuous pretreatment for 24 h
with xanomeline (Fig. 5B, open symbols). The maximal response
elicited by all three agonists was also reduced in a concentration-
dependent manner following both pretreatment conditions using
higher concentrations of xanomeline (mM range) (Figs. 5A and 5B,
closed symbols). Interestingly, xanomeline pretreatment for 24 h
elicited more potent inhibition of oxotremorine- and xanomeline-
mediated PI hydrolysis than the response mediated by carbachol.
It is also worth noting that both pretreatment conditions resulted
in a slight increase in basal response at xanomeline concentrations
of 1 mM and above (Figs. 5A and 5B, asterisks).
Comparison of the effects of treatment with carbachol or
xanomeline on agonist-stimulated production of inositol
phosphates
Our radioligand binding data indicate that long-term treatments
with xanomeline result in decreases in cell-surface receptor availability
(Fig. 2, Table 2). In order to determine if these changes play a role in
the long-term functional effects observed following xanomeline
pretreatment, additional comparative experiments were conducted
following 24-h pretreatment with carbachol. The concentration of
carbacholchosenfor these experiments was 10 mM, which displays an
equi-effective response to that of 300 nM xanomeline (Fig. 3). As can
b es e e ni nF i g s .6a n d4 ,C H Oh M 1cellspretreated with carbachol for
24 h followed by washing and subsequent agonist stimulation
(carbachol, oxotremorine, or xanomeline) exhibited alterations in
receptor sensitivity similar to those obtained following 24-h
pretreatment with xanomeline. Stimulation of carbachol-pretreated
cells with increasing concentrations of oxotremorine or xanomeline
resulted in a reduction in maximal response, while the maximal
response elicited by carbachol was not changed. Additionally, this
treatment resulted in a decrease in the potency of all the agonists used.
Results are summarized in Table 3.
Time dependence of the effects of xanomeline
pretreatment on persistent receptor activation and
agonist response
We have shown that the increase in basal receptor activity
observed following pretreatment with xanomeline for 1 h followed
by washing is reversed when cellsareallowedto incubate for 23 h in
the absence of free ligand (Fig. 4). Further experiments were
designed to determine the time course of this reversal process. CHO
hM1 cells were pretreated with 300 nM xanomeline for 1 h,
washed,thenallowedtoincubate forvarious timeperiods(0to23 h)
in ligand-free media. Alternatively, cells were pretreated continu-
ously with xanomeline for various time periods, from 30 minutes to
24 h, prior to washing and immediate use. As shown in Fig. 7A
(closed symbols), a significant increase in basal receptor activation of
PI hydrolysis was observed when cells were used immediately
following 1 h xanomeline pretreatment and washing. However,
receptor stimulation elicited by wash-resistant xanomeline binding
quickly subsided when cells were allowed to incubate in the absence
of free xanomeline, reaching control basal levels within 5 h. While
continuous treatment with xanomeline for up to 24 h also resulted
in a time-dependent reversal of persistent xanomeline receptor
activation, it occurred at a much slower rate (Fig. 7B, closed
symbols). In this case, xanomeline-induced stimulation of PI
hydrolysis remained elevated for more than 10 h.
We have also shown that pretreatment with xanomeline for 24 h
or 1 h followed by washing and waiting for 23 h resulted in an
increase in the EC50 of carbachol-mediated PI hydrolysis (Fig. 4A).
In order to determine the time course of development of this
phenomenon, parallel experiments were conducted in each of these
two paradigms where CHO hM1 cells were subsequently stimulated
with 10 mM carbachol. In both experimental designs, the ability of
carbachol to elicit PI hydrolysis was markedly reduced over time. As
can be seen in Fig. 7A (open symbols), pretreatment with
xanomeline for 1 h followed by washing and varied wait periods
resulted in a rapid decrease in carbachol-mediated PI hydrolysis,
which was maximally reduced by approximately 50% following 9 h
of incubation in the absence of xanomeline. However, when cells
were continuously exposed to xanomeline for up to 24 h, the ability
of carbachol to elicit a response subsided gradually in parallel with
that of the observed decline in xanomeline-induced persistent
receptor activation, resulting in maximal inhibition of 80% by 24 h
of xanomeline exposure (Fig. 7B, open symbols).
Comparison of the effects of xanomeline pretreatment
on [
3H]QNB and [
3H]NMS binding
The previously observed decrease in the maximal binding of
[
3H]NMS could be due to either receptor internalization or down-
Figure 3. Agonist-mediated PI hydrolysis in CHO cells stably
expressing human M1 muscarinic acetylcholine receptors. Cells
were incubated for 1 h at 37uC with increasing concentrations of
carbachol (closed squares), oxotremorine (closed triangles), or xanome-
line (closed circles). Results are expressed as percentages of maximal
carbachol elicited PI response in untreated cells (110006800 dpm).
Values represent the means 6 standard error of three experiments
conducted in triplicate.
doi:10.1371/journal.pone.0015722.g003
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3H]NMS is a permanently-charged quater-
nary amine that binds only to cell-surface receptors. Therefore,
further experiments were designed to compare the long-term effects
ofxanomeline pretreatmentonthe specificbinding of [
3H]NMSand
[
3H]QNB, a lipophilic ligand that accesses both cell-surface and
internalized (but not degraded) receptors [19]. Receptor-saturating
concentrations of both radioligands (2.9 nM [
3H]NMS; 1.4 nM
[
3H]QNB) were used in order to observe effects on receptor number
without interference from changes in radioligand affinity. As shown
in Fig. 8, the presence of xanomeline in the binding assay medium
with naı ¨ve CHO hM1 cells resulted in complete inhibition of the
binding of both radioligands in a concentration-dependent manner.
Pretreatmentwithxanomelinefor1 hfollowedbywashingawayfree
drug resulted in residual concentration-dependent inhibition of
[
3H]NMS and [
3H]QNB binding with similar lower potency than
that obtained when xanomeline was incorporated in the binding
assay medium with naı ¨ve cells. Maximal inhibition of binding of
either radioligand was incomplete. Incubation of pretreated and
washed cells for 23 h in the absence of free xanomeline resulted in
marked enhancement of the apparent potency of xanomeline in
decreasing binding of both radioligands. These changes in potency
were approximately 2.3 and 3.5 orders of magnitude greater than
those observed following washing off xanomeline, but prior to
prolonged waiting, in the case of [
3H]NMS and [
3H]QNB,
respectively. Again, maximal inhibition of binding of either
radioligand was incomplete. Continuous incubation of cells with
xanomeline for 24 h followed by washing away free drug
immediately prior to conducting the binding assay resulted in
furtherincreaseinxanomeline potencyindecreasing binding of both
radioligands. In all instances, radioligand binding was best described
by a one-site model. As previously noted, binding data were adjusted
to account for decreases in protein content following long-term
pretreatments with xanomeline. Results are summarized in Table 4.
Effects of xanomeline pretreatment on the rate of
[
3H]NMS dissociation
Wash-resistant binding of xanomeline to the M1 muscarinic
receptor results in allosteric modulation of the receptor primary
binding domain [10,12,19]. This may be reflected in an altered
rate of [
3H]NMS dissociation when dissociation is maximally
effected by receptor-saturating concentrations of atropine. There-
fore, experiments were designed to determine if the various
xanomeline pretreatments have an effect on the dissociation rate
constant (koff)o f[
3H]NMS and hence, if xanomeline is still bound
to the receptor following washing and prolonged incubation in the
absence of free xanomeline. CHO hM1 cells were subjected to the
various pretreatments with xanomeline (10 mM), then incubated
with 0.5 nM [
3H]NMS for one hour. Dissociation of the
radioligand was initiated by the addition of 10 mM atropine and
the dissociation reaction was allowed to proceed for various time
intervals. In all instances, radioligand dissociation was best
described by a monoexponential model. Pretreatment with
xanomeline for 1 h followed by washing resulted in slowing down
of the rate of [
3H]NMS dissociation by 35%. The dissociation
rates of [
3H]NMS remained the same when pretreated cells were
further incubated without free xanomeline for 23 h or pretreated
continuously for 24 h.
Figure 4. Effects of xanomeline pretreatment, followed by
washout, on agonist-stimulated PI hydrolysis in CHO cells
stably expressing human M1 muscarinic acetylcholine recep-
tors. Cells were pretreated with 300 nM xanomeline for 1 h (open
circles) or 24 h (open diamonds) followed by washing and agonist-
stimulated PI hydrolysis was measured immediately. Alternatively, cells
were pretreated for 1 h followed by washing and incubation in agonist-
free media for an additional 23 h (closed circles) before measuring
agonist-stimulated accumulation of PI hydrolysis. Sham-treated (closed
squares) and xanomeline-treated cells were subsequently incubated for
1 hour at 37uC with increasing concentrations of (A) carbachol, (B)
oxotremorine, or (C) xanomeline and accumulation of inositol
phosphates was measured. Maximal carbachol induced PI response in
untreated cells was (A) 2400061800 dpm, (B) 83006900 dpm, (C)
1900061800 dpm. Values represent the means 6 standard error of
three to eight experiments conducted in triplicate.
doi:10.1371/journal.pone.0015722.g004
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changes in receptor binding induced by xanomeline
pretreatment
We have previously shown that while xanomeline wash-resistant
binding to the M1 receptor takes place at an allosteric domain on the
receptor, receptor activation by this mode of xanomeline binding is
s e n s i t i v et ob l o c k a d eb ya t r o p i n ea n dt h e r e f o r ei n v o l v e st h er e c e p t o r
orthosteric site [10–12]. Therefore, additional binding experiments
were designed to determine whether receptor activation is required for
the induction of the observed long-term effects of xanomeline in CHO
hM1 cells. To this end, a receptor-saturating concentration of the
muscarinic antagonist atropine (10 mM) was added either simulta-
neously with xanomeline (3 mM) during the 1-h pretreatment period,
or during the 23-h period following washing off free xanomeline.
Appropriate atropine controls in the absence of xanomeline were
included. Subsequently, [
3H]NMS saturation binding isotherms were
established. As shown in Fig. 9A and Table 5, long-term changes in
receptor density were still evident following blockade of the orthosteric
site with atropine only during the initial pretreatment period.
Furthermore, atropine did not prevent persistent binding of xanome-
line to the receptor, supporting the notion that this mode of binding
occurs at a secondary site on the receptor [12,13]. In contrast, when
atropine was present only during the 23-h incubation after xanome-
line pretreatment and washing, the long-term effects of xanomeline
were completely obliterated (Fig. 9B, Table 5).
We also used specific receptor mutants to further prove a role of
receptor activation in xanomeline-mediated receptor regulation.
Our laboratory has previously shown that point mutation of
arginine-123 in the sequence of the rat M1 receptor results in nearly
complete loss of receptor responsiveness to agonists without
significant changes in receptor binding properties [21]. We utilized
this receptor mutant (mutant
123) expressed in CHO cells to
determine if a functional receptor is necessary to elicit the long-
term effects of xanomeline on radioligand binding. However,
because this mutation was done in the rat M1 receptor sequence,
necessary control experiments were performed in CHO cells
expressing rat wild-type M1 receptor (rM1) for comparison.
Xanomeline displayed a higher potency than carbachol in
stimulating PI hydrolysis in CHO rM1 cells (pEC50=7.460.11
and 5.660.10, respectively), with a slightly lower maximal response
(Emax=1800065500 dpm for xanomeline; 2300066100 dpm for
carbachol). In agreement with previous findings [21], the mutant
123
receptor did not produce a significant PI response following
stimulation with carbachol or xanomeline (data not shown).
Asanadditionalcontrol, CHOrM1or mutant
123 cellsweretreated
with 1 mM carbachol for 24 h to induce receptor down-regulation
[15,22]. Subsequent ability of 0.2 nM [
3H]NMS to bind to the
receptor was compared. As expected, [
3H]NMS binding in rM1 cells
was reduced by approximately 95% (data not shown). In contrast, no
significant reduction in [
3H]NMS binding was observed inmutant
123
cells, supporting the notion that agonist-induced receptor regulation
is indeed contingent on receptor activation (data not shown).
Experiments measuring the decrease in binding of 0.2 nM
[
3H]NMS in mutant
123 cells following the various xanomeline
pretreatment conditions were compared with those in rM1 cells. As
shown in Figs. 10A and 10B, and Table 1, xanomeline bound with
similar high potency (IC50 of approximately 50 nM) to both the
wild-type rM1 and mutant
123 receptors in naı ¨ve cells. Additionally,
short-term xanomeline wash-resistant binding in mutant
123 cells
was virtually identical to that observed in rM1 cells. However, the
long-term effects of xanomeline on [
3H]NMS binding evident in
rM1 cells were drastically attenuated by this mutation. In agreement
withourfindingsinCHOhM1 cells,nonlinear regression analysisof
data from rM1 cells resulted in a two-site binding model for both
long-term treatments, albeit at lower potencies (Table 1). In
contrast, data from the mutant
123 cells were best described in terms
ofa simplerone-sitemodelofbindinginall cases(Fig.10B,Table1).
Furthermore, continuous pretreatment with xanomeline for 24 h
Table 3. Effects of xanomeline or carbachol pretreament on activation of PI hydrolysis by carbachol, oxotremorine, or xanomeline
in CHO hM1 cells.
Pretreatment condition Agonist stimulation
Carbachol Oxotremorine Xanomeline
300 nM xanomeline pEC50
a Emax
b1 pEC50 Emax
b2 pEC50 Emax
b3
Control
c 6.060.06 9960.5 7.160.08 9264.9 7.960.40 9862.8
1 h washout n.a.
d 7562.6* n.a. 78615.6 6.460.55* 10564.5
1 h washout/23 h wait 5.060.06* 8066.9* 5.660.09* 3164.4* 6.660.03* 62614.0*
24 h washout 4.360.11* 79610.7* 5.360.29* 1563.9* 6.360.09* 2867.5*
10 mM carbachol
Control 5.960.11 9861.2 6.860.02 9866.8 7.760.11 9563.7
24 h washout 4.560.08{ 7169.9 5.760.02{ 1563.9{ 6.660.01{ 1865.2{
Cells were pretreated with 300 nM xanomeline or 10 mM carbachol for 1 h or 24 h at 37uC followed by washing and immediate use in the functional assay or for 1 h
followed by washing and further incubation in the absence of free xanomeline for 23 h. Pretreated or untreated (control) cells were then incubated with increasing
concentrations of carbachol, oxotremorine, or xanomeline at 37uC for 1 h and the accumulation of inositol phosphates was determined. Functional parameters were
derived from computer-assisted non-linear regression analysis as described in the Methods, and are presented as mean 6 S.E.M. of three to nine individual experiments
conducted in triplicate.
aNegative logarithm of the midpoint (potency) parameter.
bMaximal response. Values are expressed as % maximal response elicited by carbachol in untreated cells (
b1 2400061800 dpm;
b2 83006900 dpm;
b31900061800 dpm).
cControl, naı ¨ve cells were incubated with agonist.
dNot applicable.
*ANOVA followed by Dunnett’s post-test detected a significant difference (p,0.05) in pEC50 or Emax between the pretreated groups compared with control.
{Student’s t-test detected a significant difference (p,0.05) in pEC50 or Emax between the pretreated groups compared with control.
doi:10.1371/journal.pone.0015722.t003
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from that following short-term xanomeline pretreatment, although
maximal inhibition of [
3H]NMS binding was incomplete at 92%.
Protein content was unaffected by long-term xanomeline pretreat-
ments in rM1 and mutant
123 cells.
Similar findings were obtained in [
3H]NMS saturation binding
experiments. As can be seen in Fig. 10C and 10D, stripping the
receptor of function completely annulled the changes in receptor
density observed in rM1 cells. In contrast, all xanomeline-induced
changes in radioligand affinity observed in rM1 cells were
conserved in mutant
123 cells (Table 2).
Role of the orthosteric site in long-term changes in
receptor sensitivity induced by xanomeline pretreatment
Experiments measuring PI hydrolysis in CHO hM1 cells were
designed utilizing the muscarinic antagonist atropine to determine
the role of the receptor orthosteric site and receptor activation in
the long-term effects of xanomeline on receptor response to
agonists. As in binding studies, CHO hM1 cells were pretreated
with 300 nM xanomeline in the absence or in the presence of
10 mM atropine, either during the 1-h pretreatment period or the
23-h incubation period after free xanomeline had been washed
away. Appropriate atropine pretreatment controls in the absence
of xanomeline were included. Subsequently, cells were stimulated
with increasing concentrations of carbachol. Interestingly, the
presence of atropine during the initial 1-h pretreatment with
xanomeline preserved xanomeline wash-resistant activation of the
receptor (Fig. 11A). However, this pretreatment condition
prevented xanomeline-induced changes in carbachol potency or
maximal activation of PI hydrolysis. This is contrary to results
obtained in binding studies, where blockade of the orthosteric site
during the initial pretreatment with xanomeline did not obliterate
long-term changes in receptor number (Fig. 9A). In accordance
with saturation binding studies (Fig. 9B), the long-term attenuating
effects of xanomeline on the response to carbachol were abolished
in the presence of atropine during the 23-h incubation period
following xanomeline pretreatment and washout (Fig. 11B).
Noteworthy, prolonged pretreatment with atropine alone caused
a marked shift in EC50 of carbachol-induced accumulation of
inositol phosphates, in spite of washing off free atropine. This
change corresponds to the decrease in the affinity of [
3H]NMS
following similar treatment conditions (Fig. 9B, Table 5).
Discussion
In agreement with previous findings, we have shown that
xanomeline binds to and activates the hM1 acetylcholine receptor
in a wash-resistant manner [9–11,14]. Our current results also
indicate that persistent binding of xanomeline to the M1
muscarinic receptor elicits additional long-term alterations in
radioligand binding to the M1 receptor in the absence of free drug.
Understanding of these effects is of prime importance in relation to
the chronic use of xanomeline in the treatment of schizophrenia
[8]. Long-term exposure of cells to xanomeline was accompanied
by loss of persistent activation of hydrolysis of inositol phosphates
by xanomeline in conjunction with attenuation of receptor
activation by other agonists. Possible interpretations of these
observations include decreased receptor availability, modifications
in receptor conformation, or blockade of the receptor by
persistently-bound xanomeline. Any of these effects would result
in diminishing radioligand binding in addition to suppressing
agonist-mediated activation of the M1 receptor.
We have currently shown that acute, as well as chronic,
pretreatment with xanomeline results in long-term changes in
[
3H]NMS binding to M1 receptors. Previous reports have
indicated that similar long-term changes can occur following
exposure to xanomeline for as little as 1 minute [14]. Comparisons
with carbachol were made in the current study in order to assess
whether these effects are unique to xanomeline. As can be seen in
Figs. 1A and 1B, xanomeline pretreatments resulted in changes in
radioligand binding very distinct from those induced by carbachol.
Exposure of cells to xanomeline for 1 h followed by washing
resulted in a concentration-dependent decrease in [
3H]NMS
binding with a slightly lower potency than that seen in untreated
cellssubjectedto radioligand bindinginthepresenceofxanomeline.
This is in contrast to results obtained using carbachol for
pretreatment followed by washing, where no change in radioligand
binding was observed. Receptor internalization and down-regula-
tion induced by sustained exposure to conventional reversible
agonists are well-documented phenomena [15,16,23,24]. In
accordance with these findings, pretreatment with carbachol for
Figure 5. Antagonism of agonist-induced stimulation of PI
hydrolysis by xanomeline pretreatment in CHO cells stably
expressing human M1 muscarinic acetylcholine receptors. Cells
were pretreated with increasing concentrations of xanomeline for (A)
1 h followed by washing and incubation in agonist-free media for an
additional 23 h, or (B) 24 h followed by washing. Cells were
subsequently incubated for 1 h at 37uC in the absence (asterisks) or
presence of carbachol at 1 mM (open circles) or 10 mM (closed circles);
oxotremorine at 0.1 mM (open triangles) or 1 mM (closed triangles); or
xanomeline at 0.03 mM (open diamonds) or 0.1 mM (closed diamonds).
Maximal carbachol-induced PI response in untreated cells was (A)
1700063700 dpm, (B) 2000061000 dpm. Values represent the means
6 standard error of two to four experiments conducted in triplicate.
doi:10.1371/journal.pone.0015722.g005
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3H]NMS binding. The
resultant single high-potency binding profile following carbachol
long-term treatment was in sharp contrast to the biphasic curve
Figure 7. Time dependence of xanomeline-induced persistent
activation and antagonism of agonist-stimulated PI hydrolysis
in CHO cells stably expressing human M1 muscarinic acetyl-
choline receptors. Cells were pretreated with 300 nM xanomeline for
(A) 1 h followed by washing and incubation in agonist-free media for
the indicated time periods, or (B) continuously for the indicated time
periods before washing. Subsequently, cells were incubated for 1 h at
37uC in the absence of further agonist stimulation (closed squares) or in
the presence of 10 mM carbachol (open squares) and accumulation of
inositol phosphates was measured. Results are expressed as percent-
ages of maximal carbachol-elicited PI response in untreated cells, which
was 3200062000 dpm and 2700065000 dpm in case of A and B,
respectively. Values represent the means 6 standard error of two to
three experiments conducted in triplicate.
doi:10.1371/journal.pone.0015722.g007
Figure 6. Effects of carbachol pretreatment, followed by
washout, on agonist-stimulated PI hydrolysis in CHO cells
stably expressing human M1 muscarinic acetylcholine recep-
tors. Cells were pretreated without or with 10 mM carbachol for 24 h
followed by washing before measuring agonist-stimulated accumula-
tion of inositol phosphates. Untreated (closed squares) and carbachol-
treated (open diamonds) cells were subsequently incubated for 1 hour
at 37uC with increasing concentrations of (A) carbachol, (B) oxotrem-
orine, or (C) xanomeline and accumulation of inositol phosphates was
measured. Results are expressed as percentages of maximal carbachol-
elicited PI response in untreated cells (980061900 dpm). Values
represent the means 6 standard error of three experiments conducted
in triplicate.
doi:10.1371/journal.pone.0015722.g006
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similarbiphasiccurveresultedfollowingpretreatmentwithxanome-
line for 1 h followed by washing and waiting 23 h in xanomeline-
free media. Again, this is unlike results obtained using carbachol for
pretreatment, where no effect on radioligand binding was observed
under these conditions. In fact, previous literature has shown that
the marked decrease in binding elicited by 12-h carbachol
pretreatment is fully reversed following washing and incubation in
carbachol-free media for 24 h [22]. These observations provide
furtherevidence that xanomeline interactswiththe M1 receptorin a
manner unlike other classic muscarinic agonists.
Continuous prolonged incubation of cells with either xanome-
line or carbachol reduced receptor sensitivity in responding to
activation by agonists. As shown in Fig. 4, pretreatment with
300 nM xanomeline for 24 h resulted in antagonism of the
response to carbachol, oxotremorine and xanomeline, as evi-
denced by a reduction in potency. This was accompanied by a
marked decrease in the maximal response of only the latter two
agonists. Nearly identical results were obtained when 10 mM
carbachol was used for pretreatment (Fig. 6, Table 3). These
effects are commensurate with the occurrence of comparable
receptor internalization or down-regulation under these pretreat-
ment conditions (data not shown). However, it is interesting to
note that pretreatment with either ligand for 24 h results in a
greater effect on maximal PI hydrolysis elicited by oxotremorine
or xanomeline than on that stimulated by carbachol (Figs. 4, 5B,
and 6). While we have currently shown that both oxotremorine
and xanomeline appear as full agonists in our high receptor
expression system (Fig. 3), previous literature has suggested that
these ligands may be partial agonists at the M1 receptor [25,26].
This is supported by our observation that xanomeline and
oxotremorine exhibit a lower maximal PI response than carbachol
in rat wild-type M1 cells (data not shown) that express a lower
number of receptors compared to human M1 cells (Table 2). While
the maximal response to the full agonist carbachol should not be
affected by a reduction in receptor number in a high receptor
expression system due to the presence of spare receptors, the
response to partial agonists should be reduced, as full receptor
occupancy is necessary for such agents to elicit a maximal response
[27].
The biphasic nature of the [
3H]NMS binding displacement
curve following long-term treatments with xanomeline may
suggest that low and high concentrations of xanomeline result in
differential modes of receptor regulation. At low concentrations of
xanomeline (less than 300 nM), down-regulation or internalization
may be the predominant mechanism occurring to explain the
appearance of a high-potency phase of inhibition of [
3H]NMS
binding following treatment with xanomeline for 24 h or 1-h
pretreatment followed by washing and 23-h wait. Pretreatment
with increasing concentrations of carbachol for 24 h results in
highly potent, monophasic inhibition of 0.2 nM [
3H]NMS
binding (Fig. 1B). Additionally, [
3H]NMS saturation binding
experiments show that maximal receptor density is significantly
reduced following both protocols of pretreatment with 300 nM
Figure 8. Effects of xanomeline pretreatment, followed by
washout, on binding of receptor-saturating concentrations of
[
3H]NMS and [
3H]QNB in CHO cells stably expressing human
M1 muscarinic acetylcholine receptors. The binding of (A) 2.9 nM
[
3H]NMS or (B) 1.4 nM [
3H]QNB was measured in the presence of
increasing concentrations of xanomeline in naı ¨ve cells (closed squares),
or after pretreating with increasing concentrations of xanomeline for
1 h (open circles) or 24 h (open diamonds) followed by washing and
immediate use in the binding assay, or after pretreating with increasing
concentrations of agonist for 1 h followed by washing and incubation
in agonist-free media for an additional 23 h before use in the binding
assay (closed circles). Nonspecific binding was defined by 10 mM
atropine. Values represent the means 6 standard error of three to four
experiments conducted in triplicate.
doi:10.1371/journal.pone.0015722.g008
Table 4. Effects of various xanomeline treatment conditions
on the specific binding of [
3H]NMS or [
3H]QNB in CHO hM1
cells.
[
3H] NMS (2.9 nM) [
3H] QNB (1.4 nM)
pIC50 Imax pIC50 Imax
Control
a 6.960.08 9861.0 5.960.03 10261.5
1 h washout 5.560.20* 8063.6* 4.860.08* 6269.6*
1 h washout/23 h
wait
7.860.38 8460.4* 8.360.19* 7462.0*
24 h washout 8.860.26* 8860.6* 9.260.30* 7262.2*
Data shown in Fig. 4 were corrected for protein as indicated in results.
Parameters derived from nonlinear regression analysis are shown as mean 6
S.E.M. of three to four experiments conducted in triplicate. All other details as in
Table 1.
aControl, naı ¨ve cells were incubated simultaneously with xanomeline and the
radioligands.
*Significant difference (p,0.05) in pIC50 between the indicated groups and
control as determined by one-way ANOVA followed by Dunnett’s post-test.
doi:10.1371/journal.pone.0015722.t004
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xanomeline on receptor number is saturable. This may account for
the inflection of the inhibition of [
3H]NMS binding in cells
pretreated with increasing concentrations of xanomeline for 24 h
or for 1 h followed by washing and waiting for 23 h in the absence
of free xanomeline. Saturation binding of [
3H]NMS following 1-h
pretreatment with an intermediate concentration of xanomeline
(300 nM), washing and waiting for 23 h or treatment for 24 h with
this concentration results in an increase in [
3H]NMS affinity
(Table 2). This concentration of xanomeline coincides with the
end of the long plateau observed in displacement binding
experiments. This increase in [
3H]NMS affinity may mask further
decreases in receptor availability occurring at concentrations
within this range and contribute to the appearance of the plateau
observed in Fig. 1A.
[
3H]NMS is cell impermeable due to its permanently-charged
quaternary amine nature. Thus, the observed decrease in the Bmax
of [
3H]NMS binding by pretreatment with xanomeline for 24 h
before washout, or for 1 h followed by washing and 23-h
incubation in agonist-free medium could be due to either receptor
internalization or down-regulation. In order to differentiate
between these possibilities, further experiments were designed to
compare the concentration-dependent effects of xanomeline on
the binding of saturating concentrations of [
3H]NMS and
[
3H]QNB. While [
3H]NMS labels only cell-surface receptors,
[
3H]QNB is lipophilic and could label both cell-surface and
internalized, but not degraded, receptors [19]. As shown in Fig. 8,
xanomeline completely inhibits the binding of both [
3H]NMS and
[
3H]QNB in untreated cells. Similarly, short-term pretreatment
with xanomeline followed by washing results in comparable wash-
resistant effects on both radioligands, suggesting that acute
persistent binding of xanomeline does not result in receptor
internalization. The enhanced potency of xanomeline in decreas-
ing binding of either radioligand observed after 24-h pretreatment
or 1-h pretreatment followed by washing and waiting for 23 h
supports the notion that the long-term effects of xanomeline are
likely due to receptor degradation, where the receptors are no
longer available to either radioligand. However, the observed
similar incomplete inhibition of binding of either radioligand
under the latter two conditions suggests that a portion of the cell-
surface receptor population is not susceptible to regulation by
xanomeline. We cannot exclude the possibility of a time-
dependent potentiation of xanomeline-induced negative allosteric
effects on the binding of radioligands to cell-surface or internalized
(but intact) receptors, particularly due to the greater potentiation
of xanomeline effects on [
3H]QNB than [
3H]NMS binding.
According to the ternary model of receptor allosterism [28], the
magnitude of modulation of ligand binding at the receptor
orthosteric domain by a given allosteric agent differs from one
ligand to another.
In addition to down-regulation/internalization of the receptor,
long-term pretreatment with high concentrations of xanomeline
(mM range) results in additional modifications of the receptor.
Experiments measuring the binding of a low concentration of
[
3H]NMS following long-term pretreatments with xanomeline
demonstrated a two-site binding profile with a very distinct plateau
separating the two potency states (Fig. 1A). In contrast, similar
treatments with xanomeline exhibit a single high-potency
component in inhibiting the binding of receptor-saturating
concentrations of either [
3H]QNB or [
3H]NMS (Fig. 8). The
former radioligand binding protocol reflects decreases in either
maximal binding or the affinity of the radioligand for the receptor,
while the latter condition mainly detects effects on receptor
number.
In contrast, long-term incubations with a high concentration of
xanomeline (3 mM) leads to a decrease in [
3H]NMS affinity
obtained from saturation binding experiments (Table 2). Previous
literature has shown that acute treatment with xanomeline results
in allosteric modulation of the M1 receptor [9,11,19]. We have
currently shown that acute as well as chronic pretreatment with
xanomeline results in changes in the dissociation rate of [
3H]NMS,
which is one indicator that an allosteric interaction might be
occurring. The observed divergent effects of xanomeline pretreat-
ment on the affinity of [
3H]NMS binding may therefore suggest
that xanomeline exerts concentration-dependent allosteric effects.
Previous reports have shown that xanomeline persistently
activates the M1 receptor following pretreatment with xanomeline
for as little as 1 minute followed by the removal of free and
reversibly bound agonist [14]. Currently, we have shown that
Figure 9. Effects of atropine on the long-term effects of
xanomeline pretreatments on [
3H]NMS saturation binding in
CHO cells stably expressing human M1 muscarinic acetylcho-
line receptors. (A) Presence of atropine during 1 h pretreatment
followed by 23 h wait in ligand-free media. Cells were pretreated with
3 mM xanomeline in the presence of 10 mM atropine (open circles), or
with atropine alone (open squares) for 1 h followed by washing and
incubation for 23 h in ligand-free media. (B) Alternatively, atropine was
added during the 23 h wait following pretreatment with xanomeline
and washing. Cells were pretreated with 3 mM xanomeline (open circles)
or sham treated (open squares) for 1 h followed by washing and
incubation for 23 h in the presence of 10 mM atropine. For all
experiments, cells were subsequently incubated for 1 h at 37uC with
increasing concentrations of [
3H]NMS. Nonspecific binding was defined
by 10 mM atropine. Values represent the means 6 standard error of four
experiments conducted in triplicate.
doi:10.1371/journal.pone.0015722.g009
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pretreatment, then slowly decreases over time until no functional
activity is detected following 16 to 24 h of chronic xanomeline
treatment (Fig. 7B). Furthermore, as the duration of xanomeline
exposure is lengthened, the ability of carbachol to mediate a
response slowly decreases in parallel to the observed reduction in
xanomeline persistent receptor activation. Taken together, our
data suggest that chronic treatment with xanomeline results in
slow desensitization of the PI response, in conjunction with
receptor down-regulation. This is similar to previous findings using
carbachol to induce agonist-mediated receptor desensitization [22]
and xanomeline-induced receptor internalization observed by
confocal microscopy [29].
In contrast to results obtained following chronic xanomeline
exposure [13,14,29], a quick reversal of persistent receptor
activation was observed when cells were allowed to incubate in
the absence of free xanomeline following 1-h pretreatment, where
less than 7 h were necessary to reach control basal activity levels
(Fig. 7A). Therefore, the observed differences in receptor
desensitization between chronic xanomeline pretreatment and 1-
h pretreatment with varied incubation times in ligand-free media
may be due to a lower concentration of xanomeline at the receptor
biophase under the latter condition. Interestingly, however,
virtually identical decreases in receptor availability occur following
24-h incubation with xanomeline or 1-h pretreatment followed by
washing and waiting for 23 h. The fact that acute pretreatment
with xanomeline followed by washing results in divergent long-
term effects on receptor down-regulation and desensitization is
further evidence that the wash-resistant component of xanomeline
may act to allosterically modulate the M1 receptor.
Our data provide evidence that the long-term effects of
xanomeline are dependent upon actions at the orthosteric site that
lead to functional activation of the receptor. Blockade of the
orthostericsite with atropineduringthe 23-hwaitfollowingwashing
off free xanomeline abolished the long-term changes in Bmax as well
as the functional antagonism of carbachol-mediated PI hydrolysis
induced by xanomeline (Figs. 9B and 11B). However, changes in
Bmax were still evident when atropine was only present during the
initial pretreatment period (Fig. 9A). Taken together, these data
suggest that actions of xanomeline at the orthosteric site during the
waitingperiod (followingwashing offfree xanomeline) arenecessary
to elicit these long-term changes. It is also important to note that the
presence of atropine during the initial pretreatment period does not
prevent the persistent binding of xanomeline to the receptor, as
long-term changes in Bmax were still evident. This is in agreement
with previous findings that atropine does not interfere with the
formation of xanomeline wash-resistant binding [12,20]. However,
inadditiontopropertiesasanantagonist,atropineisknowntobean
inverse agonist [30,31]. Our current data suggest that prolonged
incubation with atropine alone followed by washing results in
marked changes in [
3H]NMS affinity and maximal binding as well
as antagonism of carbachol-mediated PI hydrolysis (Figs. 9 and 11).
While the co-incubationof atropinewithxanomeline duringthe 23-
h wait period resulted in similar effects on binding and function,
divergent effects were observed when atropine was present during
the initial pretreatment period. Xanomeline-induced changes in
binding were unaffected by the presence of atropine during the
initial pretreatment period, whereas the functional effects of
xanomeline on carbachol potency were abolished. An increase in
basal response was also observed in this pretreatment paradigm,
further complicating interpretation of these results.
Several other pieces of evidence support the need for a functional
receptor to elicit long-term changes observed following long-term
treatments with xanomeline. Our laboratory has previously
reported that point mutation of arginine-123 in the rat M1 receptor
sequence results in nearly complete loss of receptor function [21].
Using this cell line, we have shown that a functional receptor is not
necessary for xanomeline persistent binding to occur (Fig. 10 B).
However, the appearance of a second high-potency binding site is
not evident following long-term treatments in the mutant receptors,
suggesting that these long-term changes are dependent on receptor
activation (Fig. 10B). Furthermore, long-term changes in receptor
availability (Bmax) are eliminated by this mutation (Fig. 10D).
However, changes in [
3H]NMS affinity are still evident, which may
be due to interference by persistently-bound xanomeline indepen-
dent of receptor activation.
Table 5. Effects of atropine during pretreatment with 3 mM xanomeline or following washout on [
3H]NMS saturation binding
parameters and activation of PI hydrolysis by carbachol in CHO hM1 cells.
[
3H]NMS binding parameters PI hydrolysis
KD (nM) Bmax pEC50 Emax
a
Without atropine
Control (no pretreatments)
b 0.3160.02 1200061200 6.0760.09 10161.4
1 h xanomeline/washout/23 h wait 0.3660.02 24006260* 5.3660.12* 9868.9
Presence of atropine during 1 h pretreatment
1 h sham + atropine/washout/23 h wait 0.5260.09 190006800 5.8760.09 100618
1 h xanomeline + atropine/washout/23 h wait 0.5560.02 610061300* 5.8760.10 100617
Presence of atropine during 23 h wait
1 h sham/washout/23 h wait + atropine 2.460.31 1400062700 4.4260.07 8967.8
1 h xanomeline/washout/23 h wait + atropine 2.660.49 130006800 4.3260.04 110614
Cells were pretreated for 1 h with xanomeline and/or atropine followed by extensive washing and waiting for 23 h in the absence or presence of atropine. Parameters
derived from nonlinear regression analysis of data shown in Fig. 9 are presented as mean 6 S.E.M. of three experiments performed in triplicate. All other details as for
Tables 2 and 3.
aExpressed as percentage of the maximal response to carbachol in untreated cells (2500062200 dpm).
bControl, naı ¨ve cells were incubated with radioligand in binding assays, or carbachol in functional assays.
*ANOVA followed by Tukey’s post-test detected a significant difference (p,0.05) between the xanomeline pretreated groups compared with respective control/sham
treatment.
doi:10.1371/journal.pone.0015722.t005
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xanomeline exposure results in long-term changes in M1 receptor
binding and functional properties. Persistent binding of xanome-
line elicits long-term changes in the receptor binding properties
that are distinct from the profile obtained with carbachol, namely
the appearance of a biphasic binding curve. We have demon-
strated that pretreatment with high and low concentrations of
xanomeline result in differential modes of receptor regulation. It is
apparent that the effects observed at low concentrations of
xanomeline are due, at least in part, to receptor down-regulation.
Methods
Materials
[
3H]N-Methylscopolamine (82 Ci/mmol) was purchased from
DuPont (Wilmington, DE); myo-[
3H]inositol (85 Ci/mmol) was
obtained from GE Healthcare (Little Chalfont, Buckinghamshire,
UK); [
14C]inositol-1-phosphate (300 mCi/mmol) was supplied by
American Radiolabeled Chemicals (St. Louis, MO); Dulbecco’s
modified Eagle’s medium was purchased from Invitrogen (Carlsbad,
CA); geneticin was obtained from Calbiochem (San Diego, CA); and
bovine calf serum was supplied by Hyclone (Logan, UT). Xanomeline
tartrate was a generous gift from Eli Lilly & Co. (Indianapolis, IN); all
other reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Cell Culture
Chinese hamster ovary (CHO) cells stably transfected with the
human M1 muscarinic acetylcholine receptor (hM1) were provided
by Dr. M. Brann, University of Vermont Medical School. The
genes encoding the rat M1 wild-type (rM1) and a non-functional
mutant (mutant
123) muscarinic receptors were stably expressed in
CHO cells [21]. All cells were grown at 37uC for 3–4 days in
Dulbecco’s modified Eagle’s medium supplemented with 10%
bovine calf serum and 50 mg/ml geneticin in a humidified
atmosphere consisting of 5% CO2 and 95% air.
Pretreatment regimen in whole cells
Cells were pretreated in monolayer at 37uC with culture
medium in the absence or in the presence of xanomeline or
carbachol (concentrations indicated in results) as follows: (1)
Figure 10. Effects of xanomeline pretreatment, followed by washout, on [
3H]NMS binding in CHO cells stably expressing rat M1
wild-type or rat M1 mutant
123 muscarinic acetylcholine receptors. For all figures, radioligand binding assays were performed for 1 hour at
37uC using naı ¨ve cells (closed squares), or after pretreating with xanomeline for 1 h (open circles) or 24 h (open diamonds) followed by washing and
immediate use in the binding assay, or after pretreating for 1 h followed by washing and incubation in agonist-free media for an additional 23 h
before use in the binding assay (closed circles). Top row: Inhibition of binding of 0.2 nM [
3H]NMS, was measured in (A) rat wild-type or (B) rat
mutant
123 cells in the presence of increasing concentrations of xanomeline in naı ¨ve cells or after pretreating with increasing concentrations of
xanomeline. Bottom row: Saturation binding of [
3H]NMS in (C) rat wild-type or (D) rat mutant
123 cells. Cells were pretreated with 300 nM xanomeline
as described above and were subsequently incubated with increasing concentrations of [
3H]NMS. Nonspecific binding was defined by 10 mM
atropine. Values represent the means 6 standard error of four to seven experiments conducted in triplicate.
doi:10.1371/journal.pone.0015722.g010
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cells were pretreated with agonist for 1 h; (3) cells were pretreated
with agonist for 1 h and subsequently washed three times with iso-
osmotic HEPES buffer (110 mM NaCl, 5.4 mM KCl, 1.8 mM
CaCl2, 1 mM MgSO4, 25 mM glucose, 20 mM HEPES, 58 mM
sucrose; pH 7.4; 340 mOsM) to remove unbound drug from the
medium and allowed to incubate in culture medium in the absence
of free agonist for 23 h; (4) cells were pretreated continuously with
agonist for 24 h. After appropriate incubation periods, cells were
washed with HEPES buffer three times before being used in
binding or functional assays.
Competition Binding Assays
CHO hM1,r M 1, or mutant
123 cells were seeded in 24-well
plates and grown to 80–90% confluence prior to pretreatments.
Control cells were incubated in monolayer in HEPES buffer with
0.2 nM [
3H]N-methylscopolamine ([
3H]NMS ) in the presence of
increasing concentrations of xanomeline (1 nM to 100 mM) or
carbachol (0.1 mM to 10 mM) for 1 h at 37uC. In order to assess
the persistent effects of xanomeline or carbachol, cells were
exposed to the previously described pretreatment regimen
(concentrations indicated in results). Cells were subsequently
incubated in monolayer with 0.2 nM [
3H]NMS in HEPES buffer
for 1 h at 37uC. Similar radioligand binding assays were
performed in CHO hM1 cells following xanomeline pretreatments
utilizing saturating concentrations of [
3H]NMS (2.9 nM) or
[
3H]quinuclidinyl benzilate ([
3H]QNB) (1.4 nM). In all cases, free
radioligand was removed by surface washing and labeled cells
detached by the addition of 1 M NaOH. The amount of
radioactivity (disintegrations per minute) in each sample was
determined by liquid scintillation spectrometry. Nonspecific
binding was defined using 10 mM atropine.
Saturation Binding Assays
CHO hM1,r M 1, or mutant
123 cells grown in tissue culture flasks
were pretreated in monolayer at 37uC in the absence or in the
presence of xanomeline (3 mM or 300 nM) as previously
described. Cells were then harvested by trypsinization, followed
by centrifugation (3006g, 3 min) and re-suspension of the pellet in
HEPES buffer (three times). Subsequently, cells were incubated
with increasing concentrations of [
3H]NMS (0.02 to 4.5 nM) for
1 h at 37uC. Additional saturation experiments were conducted on
CHO hM1 cells following 1-h pretreatment with atropine (10 mM)
in the absence or in the presence of xanomeline (3 mM). Cells were
washed extensively and allowed to incubate for 23 h in ligand-free
media before being harvested. In a related set of experiments,
atropine was added during the 23-h incubation following washing
off free xanomeline. All experiments used 100,000 cells/assay tube
in a total volume of 1 ml. Nonspecific binding was determined
using 10 mM atropine. The reaction was terminated by filtration
on Whatman GF/C filters (Whatman Schleicher and Schuell,
Keene, NH) using a Brandel cell harvester (Brandel Inc.,
Gaithersburg, MD). Filters were washed three times with 4-ml
aliquots of ice-cold saline and dried before radioactivity (disinte-
grations per minute) was measured using liquid scintillation
spectrometry.
Assay of phospho-inositide (PI) hydrolysis
CHO hM1,r M 1, or mutant
123 cells grown in tissue culture flasks
were incubated in monolayer with culture medium containing myo-
[
3H]inositol (1 mCi/ml) for 24 h at 37uC. Labeled cells were
harvested by trypsinization, centrifuged, and washed three times in
HEPES buffer to remove unincorporated myo-[
3H]inositol.
Labeled cells were distributed to assay tubes (500,000 cells/tube),
and allowed to incubate for 15 min at 37uC. Concentration-
response curves for the stimulation of PI hydrolysis by xanomeline,
carbachol or oxotremorine were constructed. Further experiments
were designed to determine the effects of xanomeline pretreatment
on agonist-stimulated PI hydrolysis. CHO hM1 cells were
pretreated in monolayer with xanomeline (300 nM) or carbachol
(10 mM), as previously described. Subsequently, concentration-
response curves for the stimulation of PI hydrolysis by carbachol,
oxotremorine, or xanomeline were constructed. Additional
Figure 11. Atropine sensitivity of the long-term effects of
xanomeline pretreatments on carbachol-stimulated PI hydro-
lysis in CHO cells stably expressing human M1 muscarinic
acetylcholine receptors. (A) Presence of atropine during the initial
1 h pretreatment period. Cells were pretreated with 300 nM xanome-
line for 1 h in the absence (closed circles) or presence of 10 mM atropine
(open circles) followed by washing and incubation in ligand-free media
for 23 h. (B) Effects of atropine presence during the 23 h incubation
period following xanomeline pretreatment and washing. Cells were
pretreated with 300 nM xanomeline for 1 h followed by washing and
incubation for 23 h in the absence (closed circles) or presence of 10 mM
atropine (open circles). In both figures, control atropine pretreatments
were conducted in the absence of xanomeline pretreatments (open
squares). Untreated (closed squares) and treated cells were subse-
quently incubated with increasing concentrations of carbachol for 1 h
at 37uC and accumulation of inositol phosphates was measured. Results
are expressed as percentages of maximal carbachol elicited PI response
in untreated cells (2500062200 dpm). Values represent the means 6
standard error of three to seven experiments conducted in triplicate.
doi:10.1371/journal.pone.0015722.g011
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atropine (10 mM) in the absence or in the presence of xanomeline
(3 mM). Cells were washed extensively and allowed to incubate for
23 h in ligand-free media before being harvested. In a related set
of experiments, atropine was added during the 23-h incubation
following washing off free xanomeline. Subsequently, concentra-
tion-response curves for the stimulation of PI hydrolysis by
carbachol were constructed. In all cases, the reaction was allowed
to proceed in the presence of 10 mM LiCl for 1 h at 37uC after the
addition of agonist before being stopped with chloroform/
methanol (2:1) and centrifuged (4506g; 15 min).
Alternatively, cells were grown in 24-well plates and loaded with
myo-[
3H]inositol as described above. Following treatment with
increasing concentrations of xanomeline as outlined previously,
cells were washed three times in monolayer with iso-osmotic
HEPES buffer. Subsequently, cells were exposed to 1 mMo r
10 mM carbachol, 0.1 mM or 1 mM oxotremorine, or 0.03 mMo r
0.1 mM xanomeline for 1 h at 37uC in HEPES buffer containing
10 mM LiCl. In order to determine the time course of xanome-
line-induced persistent receptor activation and antagonism of
carbachol-induced PI hydrolysis, cells were treated with 300 nM
xanomeline for various times as indicated in results and washed.
Cells were then incubated in the absence or in the presence of
10 mM carbachol for 1 h at 37uC in the presence of 10 mM LiCl.
In all cases, the reaction was stopped with 0.3 M HClO4,
neutralized with 0.15 M K2CO3, and samples were centrifuged
(15006g; 15 min).
For all experiments, [
14C]inositol-1-phosphate was added to
each sample as an internal recovery standard. Total inositol
phosphates were separated by ion exchange chromatography
(AG1-X8 resin). The amount of radioactivity (disintegrations per
minute) in each sample was determined by liquid scintillation
spectrometry and adjusted for
14C recovery.
Dissociation Kinetics Assays
CHO hM1 cells grown in tissue culture flasks were pretreated in
the absence or in the presence of xanomeline (10 mM) as
previously described. Cells were harvested by trypsinization
followed by centrifugation and resuspension in iso-osmotic HEPES
buffer (three times). Cells were then incubated in HEPES buffer
with a fixed concentration of [
3H]NMS (0.5 nM) for 1 h at 37uC
using 100,000 cells/assay tube. After this period, 10 mM atropine
was added to inhibit reassociation of the radioligand. Nonspecific
binding was measured in the presence of 10 mM atropine. The
dissociation reaction was terminated by filtration as described
above. The amount of bound radioactivity was measured at
various time intervals to determine the dissociation rate of
[
3H]NMS.
Data Analysis
Data were analyzed using Prism 4.0 (GraphPad Software Inc.,
San Diego, CA). Displacement binding isotherms were analyzed
via nonlinear regression to derive estimates of IC50 (midpoint
location or potency parameter). Data were fitted according to both
one- and two-site mass-action binding models, and the better fit
was determined by an extra sum-of-squares test. Due to the non-
reversible nature of xanomeline binding, calculations of inhibition
constants (KI) from IC50 values were not performed, as this
conversion assumes reversible competitive interaction. Data from
each complete saturation binding isotherm were analyzed after
subtraction of nonspecific binding via nonlinear regression using
Prism to derive individual estimates of Bmax (total receptor density)
and KD (radioligand-receptor equilibrium dissociation constant).
Data from dissociation kinetic experiments were analyzed by
Prism according to both monoexponential and biexponential
dissociation models. Values of better fit based on an extra-sum-of-
squares F-test were taken as estimates of koff (radioligand
dissociation rate constant).
In functional assays of PI hydrolysis, raw data were corrected for
14C recovery to account for individual column differences in
efficiency. Individual concentration-response curve data were
fitted to a four-parameter logistic function using Prism to obtain
estimates of EC50 (half-effective concentration) and Emax.
Data shown are the means 6 standard error of the mean.
Comparisons between mean values were made by unpaired t-tests
or one-way ANOVA, as appropriate. A probability (p) value
,0.05 was taken to indicate statistical significance.
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